Overview

Quick Reference

Cagrilintide, also known in earlier development literature as AM833, is a long-acting synthetic amylin analog developed for research involving appetite regulation, body-weight biology, glycemic control, and metabolic signaling. Amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells and is studied for roles in satiety signaling, gastric emptying, postprandial glucagon regulation, and energy-balance biology.

Unlike GLP-1 receptor agonists, cagrilintide is built around the amylin signaling system. This makes it useful for studying amylin-specific pathways and comparing amylin biology against incretin-based models without presenting cagrilintide as a GLP-1 analog.

Mechanism and Receptor Biology

Amylin physiology

Amylin is released with insulin after nutrient intake and is investigated as part of the hormonal response to feeding. Research areas include satiety signaling, gastric emptying, food intake, glucagon secretion, and body-weight regulation.

Amylin receptor architecture

Amylin receptors are formed from calcitonin receptor components combined with receptor activity-modifying proteins. This receptor architecture is distinct from GLP-1 and GIP receptor biology.

Structural and Molecular Characteristics

Native human amylin can aggregate and form amyloid-like structures, so synthetic amylin analogs are designed to preserve amylin-like research activity while improving stability, solubility, duration of action, or manufacturability. Cagrilintide belongs to this engineered analog class.

Research Applications and Areas of Investigation

Cagrilintide research focuses on amylin receptor biology, appetite and satiety models, food-intake pathways, gastric-emptying research, glucagon regulation, and comparative metabolic hormone studies. It should be presented as an amylin analog, not as a GLP-1 analog or triple agonist.

Published Research and Development Status

Phase 2 dose-finding research

A randomized Phase 2 dose-finding trial evaluated once-weekly cagrilintide for weight-management research in adults with overweight or obesity. The study included a 26-week treatment period with dose escalation and a follow-up period. The authors reported dose-dependent body-weight reductions and waist-circumference reductions.

The published manuscript reported that cagrilintide 4.5 mg produced placebo-subtracted weight loss of approximately 7.8% at week 26 using the trial-product estimand, with an additional treatment-policy analysis reporting placebo-subtracted weight loss up to approximately 7.7%. These figures should be presented as study findings, not as product claims.

Current clinical development context

Cagrilintide has continued in registered investigational studies, including studies evaluating body-weight outcomes in people with overweight or obesity. For a research library page, these later studies should be framed as development-program context and updated when peer-reviewed cagrilintide-specific data are available.

Safety observations

Published cagrilintide studies commonly reported gastrointestinal adverse events such as nausea and related symptoms, especially during dose escalation. Safety observations should be presented factually and should not be converted into use guidance, dosing advice, or claims of clinical suitability.

Analytical Testing

HPLC purity

High-performance liquid chromatography is commonly used to estimate peptide purity. The main peak in a chromatogram represents the dominant detected component under the method conditions. Secondary peaks may represent related impurities, deletion sequences, oxidation products, or degradation products.

Mass confirmation

LC-MS or another mass-based method may be used to compare the observed molecular mass with the expected molecular mass. For modified peptides or peptide complexes, identity confirmation is especially important because the expected mass and analytical behavior may reflect the amino acid sequence, chemical modifications, or metal coordination.

COA interpretation

A batch-specific Certificate of Analysis should identify the compound, lot number, analytical method, purity result, identity-confirmation method when available, appearance, and testing date. COA documentation supports traceability but does not replace internal laboratory validation.

Stability and Laboratory Handling

Research peptides are commonly supplied as lyophilized powders because reduced water content can improve storage stability. Peptide integrity may still be affected by temperature, moisture, oxygen exposure, light, pH, concentration, and repeated freeze-thaw cycling.

General laboratory handling principles include minimizing moisture exposure, using clean technique, protecting material from unnecessary heat and light, keeping clear batch records, and following validated internal procedures for preparation and storage.

Frequently Asked Questions

What is cagrilintide?

Cagrilintide is a long-acting synthetic amylin analog studied in satiety, metabolic regulation, glucagon signaling, and body-weight biology.

Is cagrilintide a GLP-1?

No. Cagrilintide is an amylin analog and is studied through amylin receptor biology.

What did Phase 2 cagrilintide research report?

The Phase 2 dose-finding trial reported dose-dependent body-weight reductions over 26 weeks, including approximately 7.8% placebo-subtracted weight loss at the 4.5 mg dose using the trial-product estimand.

Is this medical advice?

No. This page is educational content for laboratory research contexts only.

References and Further Reading

• Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: randomized phase 2 trial. The Lancet. 2021.
• PubMed record for once-weekly cagrilintide Phase 2 weight-management research.
• ClinicalTrials.gov cagrilintide investigational study records.
• Research literature on amylin receptor biology, calcitonin receptor complexes, and receptor activity-modifying proteins.